BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.71
$0.879.84%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 6.12% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 30.06% | ||||
| Operating Income | -30.06% | ||||
| Income Before Tax | -28.93% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -28.93% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -28.93% | ||||
| EBIT | -30.06% | ||||
| EBITDA | -30.07% | ||||
| EPS Basic | 7.13% | ||||
| Normalized Basic EPS | 7.13% | ||||
| EPS Diluted | 7.13% | ||||
| Normalized Diluted EPS | 7.13% | ||||
| Average Basic Shares Outstanding | 38.82% | ||||
| Average Diluted Shares Outstanding | 38.82% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||